Oculis (NASDAQ:OCS) Price Target Lowered to $29.00 at HC Wainwright

Oculis (NASDAQ:OCS) had its price objective cut by HC Wainwright from $30.00 to $29.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a report on Tuesday, January 7th.

Oculis Price Performance

Oculis stock opened at $18.70 on Thursday. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $20.86 and a 200-day moving average price of $16.88. The firm has a market capitalization of $757.42 million, a PE ratio of -9.69 and a beta of 0.02.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, equities research analysts forecast that Oculis will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in the stock. Bellevue Group AG purchased a new stake in shares of Oculis in the fourth quarter valued at approximately $170,000. XTX Topco Ltd purchased a new position in Oculis during the 4th quarter worth $225,000. Geode Capital Management LLC raised its position in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Oculis in the 4th quarter worth $389,000. Finally, Bank of America Corp DE grew its position in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares in the last quarter. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.